Description: ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Home Page: www.abivax.com
7-11 boulevard Haussmann
Paris,
75009
France
Phone:
33 1 53 83 09 63
Officers
| Name | Title |
|---|---|
| Mr. Marc M. P. de Garidel M.B.A. | CEO & Director |
| Dr. Philippe Pouletty M.D., Ph.D. | Founder & Director |
| Mr. Didier Blondel | EVP, CFO & Board Secretary |
| Mr. Didier Scherrer Ph.D. | Chief Scientific Officer |
| Mr. Patrick Malloy | Senior Vice President of Investor Relations |
| Ms. Ida Hatoum | Chief People & Compliance Officer |
| Mr. Pierre Courteille M.B.A. | Chief Business Officer |
| Mr. Jerome Denis Ph.D. | Executive Vice President of Process Development & Manufacturing |
| Ms. Ana Sharma M.P.H. | VP & Global Head of Quality |
| Hema Keshava | Senior Vice President of Finance |
Exchange: PA
Country: FR : France
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.5786 |
| Price-to-Sales TTM: | 55.9658 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 62 |